Generated Narrative: MedicinalProductDefinition Xospata-Filmcoatedtablet Profile: MedicinalProductDefinition CH SMC - Authorized Dose Form: Film-coated tablet identifier: Medical Product Identifier/CH-01100869-0672110010000 indication: Xospata wird angewendet für die Behandlung von erwachsenen Patienten, die an rezidivierter oder refraktärer akuter myeloider Leukämie (AML) mit FMS-ähnlichen Tyrosinkinase 3 (FLT3)-Mutationen leiden. legalStatusOfSupply: A: Single dispensing requiring a medical or veterinary prescription additionalMonitoringIndicator: No Warning pediatricUseIndicator: Not authorised for the treatment in children classification: gilteritinib, Synthetic MarketingStatuses - Country Status DateRange * Switzerland No interruption of distribution reported 2020-09-24 --> (ongoing) attachedDocument: DocumentReference: identifier = http://fhir.ch/ig/ch-idmp/sid/attno#Application / Assessment Tracking Number#123456989-initial submission-Example-xyz-123; status = current; type = Information for healthcare professionals; date = 2021-11-09 00:00:00+0000 DocumentReference: identifier = http://fhir.ch/ig/ch-idmp/sid/attno#Application / Assessment Tracking Number#123456989-initial submission-Example-abc-123; status = current; type = Patient Information; date = 2021-11-09 00:00:00+0000 name productName: Xospata 40 mg, Filmtabletten Usages - Country Language * Switzerland German (Switzerland)
Xospata wird angewendet für die Behandlung von erwachsenen Patienten, die an rezidivierter oder refraktärer akuter myeloider Leukämie (AML) mit FMS-ähnlichen Tyrosinkinase 3 (FLT3)-Mutationen leiden.
A: Single dispensing requiring a medical or veterinary prescription
Not authorised for the treatment in children
No interruption of distribution reported